

CLAIMS

What is claimed is:

1. Use of an anti-CD38 antibody and a survivin inhibitor in the manufacture of a medicament for the treatment of a subject having a CD38-positive hematological malignancy, wherein the anti-CD38 antibody is of IgG1 isotype and comprises a heavy chain complementarity determining region (HCDR) 1, a HCDR2 and a HCDR3 of SEQ ID NOs: 6, 7 and 8, respectively, and a light chain complementarity determining region (LCDR) 1, a LCDR2 and a LCDR3 of SEQ ID NOs: 9, 10 and 11, respectively, and wherein the survivin inhibitor is YM155.
2. The use of claim 1, wherein the CD38-positive hematological malignancy is multiple myeloma (MM), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma (BL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL).
3. The use of claim 1, wherein the CD38-positive hematological malignancy is a plasma cell disease.
4. The use of claim 3, wherein the plasma cell disease is light chain amyloidosis (AL), multiple myeloma (MM) or Waldenstrom's macroglobulinemia.
5. The use of claim 4, wherein the plasma cell disease is MM.
6. The use of any one of claims 1-5, wherein the anti-CD38 antibody comprises a heavy chain variable region (VH) comprising an amino acid sequence that is 95%, 96%, 97%, 98%, 99% or 100% identical to that of SEQ ID NO: 4 and a light chain variable region (VL) comprising an amino acid sequence that is 95%, 96%, 97%, 98%, 99% or 100% identical to that of SEQ ID NO: 5.
7. The use of claim 6, wherein the anti-CD38 antibody comprises the VH of SEQ ID NO: 4 and the VL of SEQ ID NO: 5.

8. The use of any one of claims 1-7, wherein the anti-CD38 antibody induces CD38-positive cell killing by antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) or apoptosis.
9. The use of claim 1, wherein the anti-CD38 antibody and the survivin inhibitor in the form of the medicament are to be administered simultaneously.
10. The use of claim 1, wherein the anti-CD38 antibody and the survivin inhibitor in the form of the medicament are to be administered sequentially or separately.
11. The use of claim 9 or claim 10, wherein the anti-CD38 antibody in the form of the medicament is to be administered intravenously.
12. The use of claim 9 or claim 10, wherein the anti-CD38 antibody in the form of the medicament is to be administered subcutaneously in a pharmaceutical composition comprising the anti-CD38 antibody and a hyaluronidase.